...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Advances in Experimental Medicine and Biology >THERAPY OF METASTATIC MALIGNANT MELANOMA On the Way to Individualized Disease Control
【24h】

THERAPY OF METASTATIC MALIGNANT MELANOMA On the Way to Individualized Disease Control

机译：对个体化疾病控制方式的转移性恶性黑色素瘤的治疗

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

After decades of therapeutic frustration, the identification of some fundamental molecular drivers finally set the stage for the development of targeted therapies of metastatic malignant melanoma. With the invention of B-RAF inhibitors, targeting the mutated and activated B-RAF molecule in the MAP kinase cascade, objective responses can be achieved in about 50% of those cases harbouring this specific mutation. However, the effects are often short-lived with an average duration of 5-6 months. Hence, the challenge is to make such remissions stable and prevent secondary resistance. Currently, both the combination of targeted drugs and the invention of effective immunomodulating antibodies, e.g., anti-CTLA4 as well as anti-PDl, hold great promise to proceed on the way to individualized disease control, if not, as a remote aim, cure of this deadly cancer. Finally, progress has been made in identification and targeting of cancer stem cells, which seem to exhibit a kind of primary drug resistance and create the source of relapses and growth of clones with acquired secondary drug resistance.
机译：经过几十年的治疗挫折，鉴定一些基本的分子司机最终设定了靶向疗法的转移性恶性黑色素瘤的发展阶段。通过本发明的B-RAF抑制剂，靶向突变和活化的B-RAF分子在地图激酶级联中，可以在约50％含有这种特异性突变的情况下实现目的的反应。然而，效果通常是短暂的，平均持续时间为5-6个月。因此，挑战是使这种解除稳定并防止次级电阻。目前，靶向药物的组合和有效的免疫调节抗体的发明，例如抗CTLA4以及抗PDL，具有较高的承诺，以便在对个体化疾病控制的方式进行，如果没有，则作为遥控目标，治愈这个致命的癌症。最后，在癌症干细胞的鉴定和靶向方面取得了进展，这似乎表现出一种主要的耐药性并产生具有获得的二次耐药性的克隆的复发和生长来源。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号